Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 08 2024
0mins
Source: Newsfilter
Financial Results and Business Updates: Entera Bio Ltd. reported a net loss of $3 million for Q3 2024, with cash reserves of $6.9 million expected to last until Q3 2025. The company is advancing its oral peptide therapies, particularly EB613 for osteoporosis, and anticipates a significant FDA ruling in January 2025.
Clinical Developments: Entera is developing several innovative oral treatments, including the first oral PTH(1-34) tablet for osteoporosis, an oral GLP-1/glucagon dual agonist for obesity, and a GLP-2 tablet for short bowel syndrome, aiming to address significant unmet medical needs in women's health and metabolic disorders.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ENTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ENTX
Wall Street analysts forecast ENTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ENTX is 10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.470
Low
10.00
Averages
10.00
High
10.00
Current: 1.470
Low
10.00
Averages
10.00
High
10.00
About ENTX
Entera Bio Ltd is an Israel-based clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in areas with unmet medical need and where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Entera Bio Plans Final EB613 Protocol Submission to FDA in Q1 2026
- FDA Submission Plan: Entera Bio plans to submit the final Phase 3 protocol for EB613 to the FDA in Q1 2026, following the FDA's broad qualification of bone mineral density as a regulatory endpoint for anti-osteoporosis drugs on December 19, 2025, which is expected to enhance the company's market position in osteoporosis.
- Clinical Study Progress: The Phase 1 bridging study for Next-Gen EB613, initiated in November 2025, is progressing on schedule with results expected by the end of Q1 2026, providing significant commercial and strategic advantages for the company.
- Accelerated Treatment Program: Entera plans to accelerate its hypoparathyroidism treatment program in 2026 based on robust preclinical PK/PD data for a proprietary long-acting PTH analog announced in late December 2025, aiming to meet the urgent market demand for new therapies.
- Strategic Partnership Discussions: The company is actively engaging in strategic partnership discussions to optimize the development and commercialization pathway for its first-in-class oral peptide programs, indicating a strong commitment to investment and innovation in areas of unmet medical needs.
Continue Reading
China SXT Pharmaceuticals (SXTC) Closes $10 Million Offering, Stock Rises 17.4%
- Successful Financing: China SXT Pharmaceuticals, Inc. announced the closing of a registered direct offering valued at approximately $10 million, selling 66,666,666 Class A ordinary shares at $0.15 each to a single investor, thereby strengthening its balance sheet and boosting investor confidence.
- Financial Guidance: TG Therapeutics reported preliminary U.S. net product revenue for its multiple sclerosis therapy BRIUMVI for Q4 and full-year 2025, with shares rising 6.99% to $29.82, showcasing the company's growth potential.
- FDA Review Progress: Argenx SE's supplemental Biologics License Application for VYVGART, aimed at treating adults with acetylcholine receptor antibody seronegative generalized myasthenia gravis, has been accepted for priority review by the FDA, with a target action date of May 10, 2026, indicating potential for expanded indications.
- Market Trends: Cosmos Health Inc. saw its stock rise 6.09% to $0.4961 despite no specific news, reflecting speculative interest and momentum trading in the micro-cap healthcare sector.
Continue Reading